Newbie here, so please forgive any naivety or derailing irrelevance. But apart from a highly conditional deal with BCG and the less than stellar perfomance of Brevagen, the only shot GTG has left in the chamber is the colorectal screening tech being researched by Melb Uni. The results of which have yet to be published. If the results are good then I assume there will be an upward movement but if they are indifferent then I suspect this stock will be a dog for a long time.
My question is would anyone privilege these charts over the consideration of a company's fundamental productivity?
Add to My Watchlist
What is My Watchlist?
